Forbes

An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.

In this week’s edition of InnovationRx, we look at the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company, and more.

In utero gene therapy uses prenatal genetic screening to identify fetuses with lethal mutations and delivers corrective genes before birth.

The FDA and CDC have not yet determined for sure the source of the Cyclospora outbreak. It’s also not clear yet whether the rate of new Cyclosporiasis cases has slowed.

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.

Finding the lettuce took days. Finding Taco Bell took two months. Mastercard patented a fix in 2014 and shelved it, chasing the wrong half of the problem.

A new American Heart Association statement redefines coffee's impact on heart health, moving from historical caution to reassurance.

Healthcare has normalized click creep. Every extra checkbox steals attention from patients. It’s time for a Grand Declicking.

Yesterday the UN's General Assembly passed a near-unanimous declaration on cutting road-traffic deaths in half.

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino? The honest answer is that it can be either.

New structural variation sequencing reads long stretches of fetal DNA to pinpoint duplications, flips, and rearrangements, revealing which changes truly matter.

Carrie Ann Inaba, longtime Dancing with the Stars judge and former co-host of The Talk, talked about the many challenges she has faced with Sjögren’s disease.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

A physician explains Utah's program to let an AI chatbot renew prescriptions. Six months of data are now testing doctors, regulators and the FDA.